# US 2015/0104465 A1 · Il-19 as a biomarker of tslp treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104465 A1
- Document ID: US20150104465A1
- Status: Published application
- Kind: A1
- Application number: 14/354,070
- Filed: 2012-10-24
- Published: 2015-04-16
- Earliest claimed: 2011-10-28
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Pia Bjorck
- Web page: https://patentgrep.com/patent/US20150104465A1

## CPC

- G01N 33/6869: {Interleukin}
- A61P 11/06: Antiasthmatics
- A61P 17/04: Antipruritics
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/24: against cytokines, lymphokines or interferons
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2800/122: Chronic or obstructive airway disorders, e.g. asthma COPD
- G01N 2800/202: Dermatitis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to the use of IL-19 as a biomarker of treatment with a TSLP antagonist.

## Claims

### Claim 1

A method of treating allergic disease in a subject in need thereof comprising measuring expression of IL-19 in a sample from said subject and, if IL-19 levels in the sample are higher than a control, administering a therapeutically effective amount of a TSLP antagonist to the subject.

### Claim 2

A method for treating a subject with a TSLP antagonist comprising:
a) obtaining a first biological sample from the subject prior to administering a dose of a TSLP antagonist;
b) measuring the expression of IL-19 in the baseline biological sample,
c) administering the TSLP antagonist to the subject;
d) obtaining from the subject a second biological sample;
e) measuring the expression of IL-19 in the second sample;
f) comparing the expression of IL-19 in the second biological sample with the expression of IL-19 in the first biological sample,
and, if IL-19 levels are reduced in the second biological sample as compared to the first biological sample, administering a therapeutically effective amount of a TSLP antagonist to the subject.

### Claim 3

A method for selecting a subject from treatment with a TSLP antagonist comprising measuring expression of IL-19 in a sample from said subject and, if IL-19 levels in the sample are higher than the levels of a control, then administering a therapeutically effective amount of a TSLP antagonist to the subject.

### Claim 4

(canceled)

### Claim 5 (depends on 3)

The method of claim 3, wherein the TSLP antagonist is an anti-TSLP antibody.

### Claim 6 (depends on 3)

The method of claim 3, wherein the subject is a human subject suffering from an allergic disease.

### Claim 7 (depends on 6)

The method of claim 6, wherein the allergic disease is atopic dermatitis.

### Claim 8 (depends on 6)

The method of claim 6, wherein the allergic disease is asthma.

### Claim 9 (depends on 3)

The method of claim 3, wherein the sample is tissue sample.

### Claim 10 (depends on 3)

The method of claim 3, wherein the sample is a skin biopsy.

### Claim 11 (depends on 3)

The method of claim 3, wherein the sample is a blood sample.

### Claim 12 (depends on 3)

The method of claim 3, wherein the sample is serum.

### Claim 13 (depends on 3)

The method of claim 3, wherein the sample is sputum.

### Claim 14 (depends on 3)

The method of claim 3, wherein expression of IL-19 is determined by gene expression analysis or immunoassay.

### Claim 15 (depends on 3)

The method of claim 3, wherein expression of IL-19 is determined by an immunoassay selected from the group consisting of ELISA, RIA, Western blot, luminescent immunoassay, fluorescent immunoassay.

### Claim 16 (depends on 3)

The method of claim 3, wherein expression of IL-19 is determined by gene expression analysis, wherein said gene expression analysis is selected from the group consisting of is selected from the group consisting of Northern blotting, PCR-based, SAGE, flow cytometry-based, and DNA microarray.

### Claim 17 (depends on 3)

The method of any one of claim 3, wherein the control is one or more samples from samples from subjects that do not suffer from allergic disease.

### Claim 18 (depends on 3)

The method of claim 3, wherein the control is one or more samples from samples from subjects that do not suffer from allergic disease and are not treated with a TSLP antagonist.
